Global Head and Neck Cancer Treatment Market 2017-2021
About Head & Neck Cancer Treatment
Head and neck cancer usually starts in the squamous cells that lines the moist, mucosal surface present inside the head and neck. This type of cancer is further categorized by the affected areas such as oral cavity cancer, laryngeal cancer, pharyngeal cancer and other head and neck cancer. Other head and neck cancer includes salivary gland cancer, nasal cavity, and paranasal sinuses cancer.
Technavio’s analysts forecast the global head & neck cancer treatment market to grow at a CAGR of 8.07% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global head & neck cancer treatment market for 2017-2021. To calculate the market size, the report considers sales of both branded and generic drugs in the global head and neck cancer treatment market.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Head & neck cancer treatment market 2017-2021
Technavio recognizes the following companies as the key players in the global head & neck cancer treatment market: Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer.
Other Prominent Vendors in the market are: Amgen, Dr. Reddy's Laboratories, GlaxoSmithKline, Mylan, Sun Pharmaceutical Industries, Takeda Pharmaceuticals, and Teva Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is outpatient care for head and neck cancer patients. Outpatient care for the cancer patients have been found to be equally effective compared with the inpatient care. In the outpatient treatment, the cancer patient can receive the treatment at their desired place, home being one of them.”
According to the report, one driver in the market is rising incidence of head and neck cancer. Rising incidence of the head and neck cancer is the major factor leading to the higher demand of the drugs and treatment. Apart from alcohol and tobacco consumption, HPV infection is turning out to be one of the major causative agents responsible for rising incidence of the disease. Approximately 70-90% of new oropharyngeal cancers have evidence of HPV.
Further, the report states that one challenge in the market is severe side effects of drugs. There are large number of side effects associated with the treatment of head and neck cancer. This has been a major challenge for the market. The aim of the treatment is to get rid of the cancerous cells. However, these treatments can have different effects on different people, as each set of drugs used for the treatment have its own type of side effect.
Bristol-Myers Squibb, Eli Lilly, Merck, Pfizer, Amgen, Dr. Reddy's Laboratories, GlaxoSmithKline, Mylan, Sun Pharmaceutical Industries, Takeda Pharmaceuticals, and Teva Pharmaceuticals.